Drug intelligence / Profile preview

Calcicor

Development stage: Unknown
Lead developer: Emblazon Life Sciences
Modality: Small Molecules
Administration: Oral

Overview

**Calcicor** is an oral fixed-dose bone-health product marketed by Emblazon Life Sciences. A retailer listing identifies its active constituents as coral calcium and vitamin D3, used to provide calcium and support bone strength and prevention of bone breakage. The vitamin D3 component promotes intestinal calcium absorption following metabolic activation, while coral calcium supplies calcium for mineral homeostasis and bone mineralization. ([wellnessforever.com](https://www.wellnessforever.com/product/calcicor-10tab))

Brand names: Calcicor

Targets

NR1H3 (Liver X receptor beta)HRH3 (Histamine Receptor H3)NOP (Nociceptin/orphanin FQ peptide receptor)VDR (Vitamin D receptor)PDE3A (Phosphodiesterase 3A)PDE5 (Phosphodiesterase 5A)PTCH1 (Patched 1 Protein)CNR1 (Cannabinoid receptor 1)

Beyond the preview

Go deeper on Calcicor.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Calcicor.

Explore the full profile